TIAP is incredibly proud to have been able to play a significant role in the HDAX Therapeutics story, supporting the company from its inception — first through our UTEST, University of Toronto program — and now by co-leading its pivotal first closing of a $4.3M CA seed round announced today. Positioned at the forefront of developing next-generation HDAC6-targeting therapeutics to improve patient outcomes, HDAX is a tremendous example of the type of highly innovative and highly promising #Ontario #lifesciences ventures we are building in collaboration with our ecosystem partners. Congratulations to founders Nabanita Nawar, PhD and Pimyupa Manaswiyoungkul, PhD on successfully reaching this major milestone — we look forward to continuing to stand beside you and the entire HDAX team as you keep making major strides on your entrepreneurial journey! Read the full announcement at: https://shorturl.at/d3cjj Federal Economic Development Agency for Southern Ontario | Agence fédérale de ...
Congratulations Nabanita Nawar, PhD and Pimyupa Manaswiyoungkul, PhD.
CDL-Global Cancer Stream Lead and CDL-Global Head of Venture Recruitment; Supporting the Commercialization of Science and Technology
1moCongratulations Nabanita Nawar, PhD and team! A massive accomplishment.